Loading...
•
Dec 31, 2023
Fulcrum Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year of 2023, and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported collaboration revenue of $0.9 million, R&D expenses of $19.0 million, and G&A expenses of $9.9 million for Q4 2023. The company's cash, cash equivalents, and marketable securities were $236.2 million as of December 31, 2023.
On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024.
Restart of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) underway.
Cash, cash equivalents, and marketable securities were $236.2 million as of December 31, 2023.
Collaboration revenue was $0.9 million for the fourth quarter of 2023.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
Fulcrum continues to expect that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into 2026.